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ABSTRACT
Objectives: A recent individual patient data (IPD)
meta-analysis suggested that patients with moderate or
severe acute respiratory distress syndrome (ARDS)
benefit from higher positive end-expiratory pressure
(PEEP) ventilation strategies. However, thresholds for
continuous variables (eg, hypoxaemia) are often
arbitrary and linearity assumptions in regression
approaches may not hold; the multivariable fractional
polynomial interaction (MFPI) approach can address
both problems. The objective of this study was to
apply the MFPI approach to investigate interactions
between four continuous patient baseline variables and
higher versus lower PEEP on clinical outcomes.
Setting: Pooled data from three randomised trials in
intensive care identified by a systematic review.
Participants: 2299 patients with acute lung injury
requiring mechanical ventilation.
Interventions: Higher (N=1136) versus lower PEEP
(N=1163) ventilation strategy.
Outcome measures: Prespecified outcomes included
mortality, time to death and time-to-unassisted
breathing. We examined the following continuous
baseline characteristics as potential effect modifiers
using MFPI: PaO2/FiO2 (arterial partial oxygen pressure/
fraction of inspired oxygen), oxygenation index,
respiratory system compliance (tidal volume/(inspiratory
plateau pressure−PEEP)) and body mass index (BMI).
Results: We found that for patients with PaO2/FiO2
below 150 mm Hg, but above 100 mm Hg or an
oxygenation index above 12 (moderate ARDS), higher
PEEP reduces hospital mortality, but the beneficial
effect appears to level off for patients with very severe
ARDS. Patients with mild ARDS (PaO2/FiO2 above
200 mm Hg or an oxygenation index below 10) do not
seem to benefit from higher PEEP and might even be
harmed. For patients with a respiratory system
compliance above 40 mL/cm H2O or patients with a BMI
above 35 kg/m2, we found a trend towards reduced
mortality with higher PEEP, but there is very weak
statistical confidence in these findings.
Conclusions: MFPI analyses suggest a nonlinear effect
modification of higher PEEP ventilation by PaO2/FiO2
and oxygenation index with reduced mortality for some
patients suffering from moderate ARDS.
Study registration number: CRD42012003129.
BACKGROUND
Acute respiratory distress syndrome (ARDS)
carries a high mortality risk of over 40%.1 2 The
ARDS deﬁnition task force proposed three
stages of ARDS severity based on degree of
hypoxaemia: mild (200 mmHg<PaO2/FiO2≤
300 mmHg), moderate (100 mmHg<PaO2/
FiO2≤200 mmHg) and severe (PaO2/FiO2<
100 mmHg).3 Low tidal volumes and low
inspiratory pressures are considered standard
Strengths and limitations of this study
▪ This individual patient data meta-analysis of
critically ill patients with acute respiratory distress
syndrome (ARDS) investigated possible interactions
between continuous baseline characteristics and
ventilation strategies.
▪ We used multivariable fractional polynomials
interaction analyses to create treatment effect
functions for qualitative assessment of the inter-
actions; results suggest a benefit of higher posi-
tive end-expiratory pressure (PEEP) in patients
with moderate ARDS, but uncertainty remains.
▪ Although over 2000 patients from three rando-
mised trials were included, the study may still be
underpowered for analysis of interaction.
▪ The findings need further validation in external
data sets to definitively inform clinical
decision-making
Kasenda B, et al. BMJ Open 2016;6:e011148. doi:10.1136/bmjopen-2016-011148 1
Open Access Research
to prevent lung injury,4 5 but the optimal level of positive
end-expiratory pressure (PEEP) remains under debate. We
recently conducted a systematic review and individual
patient data meta-analysis (IPDMA) of three randomised
clinical trials and concluded that across all patient groups,
higher PEEP ventilation strategies are not clearly better
than lower PEEP levels in ventilated patients. However,
within the predeﬁned subgroup of patients who had mod-
erate or severe ARDS (PaO2/FiO2<200 mmHg), results
suggested a beneﬁt of high PEEP across a number of out-
comes including time-to-unassisted breathing and hospital
mortality.6 In this previous review, we used an accepted
200 mm Hg threshold7 to examine this subgroup of
patients with ARDS and used conventional statistical tests
for interaction; we also assessed interactions with other con-
tinuous variables, such as body mass index (BMI), by
assuming linearity or categorising them into quintiles.
For continuous variables, creating categories of sub-
groups remains the usual approach to investigating a
potential treatment-modifying effect (subgroup
effect).8 9 However, critics have pointed out serious
weaknesses in the categorisation approach.10–13
Methodological concerns regarding creating dichoto-
mies or discrete categories of an inherently continuous
predictor (eg, PaO2/FiO2, age or BMI) include: depend-
ence of the statistical signiﬁcance on the number and
position of the chosen cut-points, loss of statistical power
and faulty interpretation of the results if a nonlinear
association is incorrectly assumed to be linear.14 One of
the main recommendations in a series of four papers
from the PROGnosis RESearch Strategy (PROGRESS)
group15 states: ‘Standards in statistical analyses of prog-
nosis research should be developed which address the
multiple current limitations. In particular, continuous
variables should be analysed on their continuous scale
and nonlinear relationships evaluated as appropriate’.
To address the latter point, Royston and Sauerbrei13 pro-
posed the multivariable fractional polynomials inter-
action (MFPI) approach to investigate potential
treatment modifying effects in a clinical trial. MFPI esti-
mates a continuous function to quantify the relative
effect of two treatments depending on a continuous pre-
dictor of interest (treatment effect function, TEF). This
TEF can be helpful for informed decision-making.
Analyses of interactions are interesting for single trials,
as well as highly relevant for meta-analyses. Sutton et al16
have provided a comprehensive overview of many issues
and developments in meta-analysis. However, approaches
to combine results from several studies in a summary
estimate of the functional relationship between a con-
tinuous covariate and an outcome have received more
attention only in recent years. In the context of continu-
ous risk or prognostic factors, Sauerbrei and Royston17
have proposed a new strategy for meta-analysis of func-
tions, provided individual participants data (IPD) are
available for the estimation of functions in each of the
studies. Obviously, this meta-analysis approach can also
be used to derive an averaged TEF summarising single
TEFs from several MFPI analyses of randomised trials.
To improve on several critical issues from
cut-point-based meta-analyses, we started this project.
The key ingredients were all available: IPD from all ran-
domised trials for a speciﬁc treatment comparison, the
MFPI approach to estimate a TEF in each study, the
meta-analysis approach to average several TEFs across
studies and the required software.18 In 2012, four of us
have registered the protocol of this study (ICEM study)
which was extended to a publication.19
In the present study, we reanalysed data of our previ-
ously reported IPDMA6 with respect to hospital mortal-
ity, time-to-death and time-to-unassisted breathing. We
used the MFPI approach to derive a TEF function for
each study separately and derive an averaged TEF func-
tion with the meta-analysis approach for functions. On
the basis of earlier analyses and general discussions in
the literature, we hypothesised that patients with a low
PaO2/FiO2 or high oxygenation index and still good
respiratory system compliance at baseline (moderate
ARDS) have the most recruitable lung units and would
therefore beneﬁt most from higher levels of PEEP. For
patients at either end of the spectrum (mild ARDS or
very severe ARDS), higher PEEP might not provide any
beneﬁt. We did not anticipate any speciﬁc direction of
interaction effect for BMI.
PATIENTS AND METHODS
The rationale and methodological background of this
study have been described elsewhere;19 the protocol is
registered with PROSPERO (CRD42012003129 at
http://www.crd.york.ac.uk/prospero). Brieﬂy, the
present analyses were based on individual patient data
from three randomised clinical trials20–22 (N=2299
patients), all identiﬁed through a systematic review of
the literature.6 All trials investigated the beneﬁts and
harms of higher PEEP ventilation compared to lower
PEEP ventilation in patients with ARDS. Inclusion cri-
teria, literature search strategies and main results of this
individual patient data meta-analysis have been reported
previously in accordance with the PRISMA statement
(ﬁgure 1).6 23
Clinical outcomes
Hospital mortality at 60 days postrandomisation consti-
tuted the primary outcome of interest. We also consid-
ered hospital mortality as a time-to-event variable. All
trials (LOVS, ALVEOLI, EXPRESS)20–22 followed
patients for at least 60 days; thereafter, LOVS and
ALVEOLI followed the majority of patients until
death or hospital discharge, but EXPRESS did not.6 In
the current analysis, as in the original IPDMA, we
administratively censored surviving patients in the
time-to-event analysis at day 60.6 We also investigated
time-to-unassisted breathing, which was deﬁned as time
from randomisation until breathing without mechanical
support within the ﬁrst 28 days. Owing to differential
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follow-up across trials for this outcome beyond day 28
and the fact that the intervention effect is likely to
precede day 28, as in the original meta-analysis, we
administratively censored patients at day 28.6 Patients
who died before achieving unassisted breathing within
the ﬁrst 28 days were censored at the day of death. We
are aware of the problem of competing risks in intensive
care trials,24 but the MFPI approach has not yet been
adapted for a competing risk analysis. To address this,
we therefore used a cause-speciﬁc Cox model,25 26 to
assess the direct effect of higher versus lower PEEP on
the cause-speciﬁc hazard of unassisted breathing.
Pneumothorax requiring chest tube drainage during the
ﬁrst 28 days after randomisation is the main safety
outcome; owing to competing risks of pneumothorax
with mortality and as yet undeveloped MFPI method-
ology for a competing risk framework, we did not
include this outcome in the present analysis.
Potential effect modifiers and investigations
All of the following four potential effect modiﬁers were
baseline patient characteristics measured at randomisa-
tion and the analyses for potential interaction were all
prespeciﬁed in our published protocol.19 BMI at base-
line was calculated by the ratio of body weight in kg/
(height in m)2. Respiratory system compliance was calcu-
lated by the ratio of the tidal volume/(inspiratory
plateau pressure−PEEP), hypoxaemia was expressed as
the ratio of PaO2/FiO2 and oxygenation index was
deﬁned as mean airway pressure ×100/(PaO2/FiO2).
A ‘pair’ of a potential modiﬁer (eg, BMI) and an
outcome (eg, in-hospital mortality) was considered as
one investigation. In total, with 4 potential modiﬁers
and 3 outcomes, we had 12 investigations for each trial
separately and for the meta-analysis.
MFPI procedure
For each included trial, we used the MFPI approach13 to
investigate potential interactions between treatment
assignment (higher vs lower PEEP) and each of the four
potential effect modiﬁers with respect to hospital mor-
tality, time to death and time-to-unassisted breathing.
When writing the protocol for this study,19 we decided
to use only fractional polynomial (FP) degree 2 (FP2)
functions for the analysis of interactions and to select
the two power terms which ﬁt the data best. We deter-
mined the two power terms separately for each study,
giving the best ﬁt in all patients, which corresponds to
the default algorithm.13 For more technical details and
the discussion of three ‘more ﬂexible’ variants of the
algorithm, we refer to Royston and Sauerbrei 2009.18
Using the derived power terms, MFPI estimates for
each treatment group a FP function representing the
prognostic effect of the continuous covariate of interest,
optionally adjusting for other covariates. The difference
between the functions for the treatment groups is calcu-
lated and tested for signiﬁcance. The testing is per-
formed through an analysis of interaction between
treatment and the FP function. A plot of the difference
(eg, odds or hazard ratio (HR)) against the covariate,
Figure 1 Trial flow.
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together with a CI, visualises the resulting TEF. A TEF
for a continuous covariate not interacting with treatment
would be a straight line parallel to the x-axis, whereas a
treatment–covariate interaction would be indicated by a
non-constant line, often increasing or decreasing. For
further explanations and references, we refer to a dedi-
cated website on MFP and several related issues such as
interactions and meta-analyses.27
All MFPI analyses were adjusted for three potential
confounders (see below). To quantify the magnitude of
effects, we estimated odds or HRs with pointwise 95% CI
as a continuous TEF, which we plotted separately for
each study.
Averaging the functions of individual studies—
meta-analysis
We conducted an MFPI analysis with all included
patients. For each modiﬁer-outcome pair, we used
ﬁxed-effect models and weighted averaging to obtain an
averaged TEF based on all three trials as previously out-
lined.17 Usually, in a meta-analysis, the weight of a study
is determined by criteria such as the sample size, effect-
ive sample size (for a survival outcome) and variances of
estimates of interest. However, such criteria do not
reﬂect different distributions of a continuous variable.
Depending on inclusion and exclusion criteria and
further issues, such distributions may be very different
between the studies. Therefore, a study may hardly have
any information in a speciﬁc range of the data and cor-
responding CI of the treatment effect function are very
broad in such regions, reﬂecting the severe uncertainly
in this region. To reﬂect this information in the
meta-analysis, Sauerbrei and Royston17 have proposed to
average functions pointwise, with weights for each study
depending on the information at each speciﬁc point.
For a survival outcome, distribution of events and also of
the patient population inﬂuence the weights. For more
details, we refer to section 4.2 in ref. 17. Owing to the
small number of studies, we decided to use ﬁxed-effect
models and corresponding weights for each function.
For averaging the functions across studies, these were
derived from the reciprocal of the variances; pointwise,
95% CIs were calculated accordingly.17 For each poten-
tial modiﬁer, we illustrated the study weights graphically.
The averaged TEFs were plotted to allow for a qualitative
assessment of the possible interaction. Although it is pos-
sible to calculate a joint p value for the meta-analysis of
several functions, we did not calculate it because treat-
ment effect functions were nonlinear and the qualitative
assessment of the functional relationship, rather than a
single test for signiﬁcance, is of central interest.
Adjustment for confounders
All patients were analysed in the group to which they
were randomised (intention-to-treat principle). Owing to
some imbalances with respect to age20 21 and the pro-
portion of patients with severe sepsis,21 22 all MFPI ana-
lyses (for single trials and meta-analysis) were adjusted
for the following potential confounders: age (continu-
ous), presence of severe sepsis (yes vs no) and pre-
dicted probability of dying in the hospital (based on
Acute Physiology and Chronic Health Evaluation II and
Simpliﬁed Acute Physiology II scores, which have
similar accuracy28 29). We applied the function selec-
tion strategy to the confounders separately for each
study, with FP1 as the most complex permitted func-
tional form.
Missing values and influential points
Some of the potential modiﬁers and variables used for
adjustment had missing values of up to about 30%. In
order to use all information in all analyses, we imputed
missing values by multiple imputations chained equa-
tions techniques.30 The ﬁrst imputation was used for all
analyses. Further details about the multiple imputations
are provided in the appendix. To circumvent the issue
of possible inﬂuential outliers, we truncated each con-
tinuous predictor at the 1% and 99% centile, meaning
that values below/above the 1%/99% centile were
replaced by the value of the 1%/99% centile, respect-
ively. For all analyses, we used the software STATA V.13.0
(Texas, USA).
RESULTS
Patient characteristics
Table 1 summarises patients’ characteristics and clinical
outcomes stratiﬁed by trial. Overall, 2299 patients were
considered in the analysis; the effective sample size
(number of events) for hospital mortality (binary
outcome) was 783 (34.1%) (higher PEEP 374 (32.9%),
lower PEEP 409 (35.2%)) and 1465 (63.7%) patients
came off the ventilator (higher PEEP 741 (65.2%),
lower PEEP 724 (62.2%)).
Interpretation of TEFs
The respective TEF graphs (ﬁgure 2 shows averaged
effects from the meta-analysis and online supplementary
appendix ﬁgure 1–3 shows effects for the individual
studies) show the relationship between the continuous
patient characteristic (on the X-axis, eg, BMI) and the
beneﬁt/harm (eg, expressed as OR on the Y-axis) from
the intervention (higher vs lower PEEP). If the average
effect (dashed bold line) is below the horizontal line,
this suggests a treatment beneﬁt from higher PEEP and
a detrimental effect if it is above. It is the opposite for
the end point time-to-unassisted breathing, because
here the outcome of interest is the ‘positive’ event
coming off the ventilator. The thin dashed lines repre-
sent the pointwise upper and lower 95% CI limit.
Therefore, at those parts where the 95% CI includes the
horizontal line (OR or HR is 1), it is uncertain whether
the suggested beneﬁt or harm is real. The dashed verti-
cal lines indicate the 5% and 95% centile of the data of
the continuous predictors.
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Table 1 Selected patient characteristics and end points
LOVS EXPRESS ALVEOLI ALL
Characteristics
Higher PEEP
N=475
Lower PEEP
N=508
Higher PEEP
N=385
Lower PEEP
N=382
Higher PEEP
N=276
Lower PEEP
N=273
Higher PEEP
N=1136
Lower PEEP
N=1163
Age 54.5 (16.5) 56.9 (16.5) 60.1 (15.7) 59.7 (15.1) 53.7 (17.1) 48.5 (16.9) 56.2 (16.6) 55.9 (16.7)
Women, N (%) 193 (40.6) 201 (39.5) 125 (32.9) 126 (33.2) 119 (43.1) 128 (46.9) 437 (38.5) 455 (39.1)
BMI 27.5 (6.5,
(23.1–30.4))
27.2 (6.8,
(23.0–30.1))
26.3 (5.8,
(22.5–29.0))
26.3 (6.1,
(22.4–29.2))
27.8 (6.8,
(22.7–30.7))
27.2 (7.0,
(22.1–30.2))
27.2 (6.4,
(22.9–30.1))
26.9 (6.6,
(22.6–30.0))
Missing values, N (%) 72 (15.2) 85 (16.7) 17 (4.4) 19 (5.0) 23 (8.3) 21 (7.7) 112 (9.6) 125 (10.7)
PaO2/FIO2 145.1 (48.3,
(106.7–177.8))
144.7 (49.1,
(105.5–181.3))
144 (57.6,
(101.7–180.0))
142.7 (56.9,
(94.3–180.0))
151 (67.3,
(102.0–191.4))
163 (76.2,
(105.0–207.5))
146 (56.6,
(103.3–180.0))
148.4 (59.5,
(101.7–186.0))
Missing values, N (%) 1 (0.2) 2 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 2 (0.2)
Oxygenation index 14.4 (8.3,
(8.7–17.2))
14.4 (8.1,
(8.5–18.0))
13.1 (7.6,
(7.9–16.0))
13.0 (8.2,
(7.4–16.1))
13.1 (8.5,
(7.4–16.7))
12.1 (8.0,
(6.8–15))
13.6 (8.1,
(8.2–16.8))
13.4 (8.2,
(7.8–17.0))
Missing values, N (%) 51 (10.7) 63 (12.4) 80 (20.8) 73 (19.3) 16 (5.8) 18 (6.6) 147 (12.9) 154 (13.2)
Estimated RC 33.4 (16.9,
(21.9–35.8))
35.8 (21.6,
(23.2–36.7))
33.0 (12.3,
(24.3–40.0))
33.0 (11.6,
(24.0–40.0))
36.0 (20.7,
(23.5–41.7))
31.2 (12.8,
(22.2–37.5))
33.9 (16.6,
(23.1–39.0))
33.8 (17.1,
(23.3–38.5))
Missing values, N (%) 148 (31.2) 170 (21.1) 12 (3.1) 12 (3.1) 34 (12.3) 35 (12.8) 194 (17.1) 217 (18.7)
Probability of death* 52.9 (23.5) 55.7 (23.2) 45.8 (26.6) 44.5 (27.0) 49.0 (21.8) 47.1 (21.1) 49.6 (24.4) 50.0 (24.6)
Missing values, N (%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.1) 3 (1.1) 3 (0.3) 3 (0.3)
Severe sepsis, N (%) 214 (45.1) 248 (48.7) 285 (75.0) 268 (70.7) 96 (34.8) 112 (41.0) 595 (52.4) 628 (54.0)
Deaths in hospital, N (%) 162 (34.1) 192 (37.7) 136 (35.8) 149 (39.3) 76 (27.5) 68 (24.9) 374 (32.9) 409 (35.2)
Pts achieved UAB, N (%) 309 (65.1) 315 (62.0) 237 (61.6) 210 (55.7) 195 (70.7) 199 (72.9) 741 (65.2) 724 (62.2)
Barotrauma, N (%) 45 (9.5) 38 (7.5) 26 (6.8) 22 (5.8) 16 (5.8) 15 (5.5) 87 (7.7) 75 (6.4)
Values are means (SD, (IQR)) unless specified otherwise. Summary statistics of the characteristics are based on the imputed data set.
*According to APACHE II and SAPS scores.
BMI, body mass index; RC, respiratory compliance (tidal volume in mL/inspiratory plateau pressure−PEEP in mm Hg); PEEP, positive end-expiratory pressure; PaO2, arterial partial oxygen
pressure (mm Hg); FiO2, fraction of inspired oxygen; Pts, patients; UAB, unassisted breathing.
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Interaction in single trials
We present a p value for each test of interaction (poten-
tial effect modiﬁers x higher PEEP) with the MFPI
approach separately for each trial (table 2). Nearly all p
values are much larger than 0.05. Only two p values in
the LOVS trial are below this value. This may indicate
that there are few, if any, interaction effects, but it has to
be noted that RCTs are usually not powered to detect
interactions and these values may also be a result of low
power in individual studies. The corresponding TEFs are
shown in the online appendix (see online
supplementary appendix ﬁgures 1–3). Some of the esti-
mated treatment effect functions point towards an effect
depending on the continuous variable, but all pointwise
CIs are large because of the small effective sample size.
Please note that FP power terms were estimated separ-
ately in each study and differ slightly. For the
meta-analysis, FP2 power terms given in online
supplementary appendix table 1 were used for each of
the studies. Corresponding functions may differ slightly.
Interaction in meta-analysis
Figure 2 illustrates the adjusted averaged TEFs for each
modiﬁer-outcome pair (meta-analysis). Figure 3 sum-
marises the distributions of weights given to each trial to
calculate the averaged TEFs. The shape of these curves is
mainly a result of the distribution of the respective modi-
ﬁer and corresponding number of events. For example,
in the EXPRESS trial, there were more deaths (280 vs
134) compared to the ALVEOLI trial in the group of
patients with BMI <40 kg/(height in m)2, while the
ALVEOLI trial contributed more events (10 vs 5) in the
group of patients with BMI above 40 kg/(height in m)2
(ﬁgure 3, left upper cell).
BMI: The ﬁrst row of ﬁgure 2 shows TEFs averaged
over the three individual trials illustrating the potential
Figure 2 Averaged TEFs based on fixed effects of each predictor-outcome pair. The vertical dashed lines include 95% of the
data of the continuous predictors; the horizontal line at the OR or HR of 1 denotes equivalence of treatment effects; thus, a TEF
parallel to the horizontal line indicates no treatment interaction. For the outcomes, 60 days in hospital mortality and time to death
values beneath this line indicate that higher PEEP is more effective than lower PEEP. For the outcome time-to-unassisted
breathing, it is the other way round. BMI, body mass index; OI, oxygenation index; PaO2/FiO2, PaO2/FiO2 ratio; PEEP, Positive
end-expiratory pressure; RC, respiratory compliance; TEF, treatment effect function.
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interaction between BMI and the clinical outcomes.
Regarding all three outcomes, the TEFs do not suggest
particular interactions. However, regarding hospital mor-
tality and time to death, the 95% CIs are considerably
wide, especially at both ends, which leaves much uncer-
tainty about the interaction effect. TEFs of the individual
trials differ slightly but none of the individual RCTs
showed a signiﬁcant interaction between BMI and PEEP
intervention for any of the three outcomes (see online
supplementary appendix ﬁgures 1–3).
Respiratory system compliance: The second row of
ﬁgure 2 shows TEFs averaged over the three individual
trials illustrating the interaction between respiratory
system compliance and the clinical outcomes. For values
larger than about 40 (tidal volume in mL/(inspiratory
plateau pressure−PEEP)), the function indicates some
advantage for higher PEEP levels regarding hospital
mortality and time to death, but the uncertainty of this
interaction rapidly grows for values below 30 and above
60 (tidal volume in mL/(inspiratory plateau pressure
−PEEP)) for hospital mortality. The TEF for
time-to-unassisted breathing showed a different shape,
suggesting that only a small group of patients with values
between 35 and 50 (tidal volume in mL/(inspiratory
plateau pressure−PEEP)) may beneﬁt from higher PEEP
ventilation.
PaO2/FiO2: The third row of ﬁgure 2 shows TEFs aver-
aged over the three individual trials illustrating the inter-
action between PaO2/FiO2 and the outcomes. They
suggest that patients with values below 150 but above
100 mm Hg (moderate ARDS) may beneﬁt with respect
to all three outcomes; however, the CIs in this range are
still wide and barely exclude the odds and HR of 1,
reﬂecting some remaining uncertainty about the treat-
ment modifying effect of PaO2/FiO2. At both ends, 95%
CIs are very wide and the functions for odds and HRs
hardly exclude ‘1’ for any value, leaving a high degree
of uncertainty.
Oxygenation index: The fourth row of ﬁgure 2 shows
a similar pattern for the oxygenation index as described
for PaO2/FiO2. On the basis of the averaged TEF for
hospital mortality, there is evidence for a beneﬁt from
higher PEEP for patients with an oxygenation index
above 12 that becomes smaller for values above 18.
Regarding time to death and time-to-unassisted breath-
ing, the rather ﬂat shape of all TEFs suggests that no
interaction is present.
As requested by one reviewer, we give more details of
all main effect models (single trials and meta-analysis)
in the online supplementary appendix tables 1–4.
DISCUSSION
Summary of findings
In this meta-analysis of three randomised trials, we have
combined two novel approaches to investigate interac-
tions between continuous baseline patient characteristics
with two ventilation strategies (high vs lower PEEP) and
to average resulting functions in a meta-analysis.
Although the statistical conﬁdence in most interaction
effects is very weak, the visual inspection of averaged
TEFs suggests that some patients with moderate ARDS
may beneﬁt from higher PEEP ventilation with respect
to hospital mortality, time to death and
time-to-unassisted breathing. Patients with severe obesity
were excluded from all included trials; therefore,
although the TEF for BMI may suggest mortality reduc-
tion with higher PEEP ventilation in patients with very
high BMI, no conclusions for the clinical practice can
be made, because the uncertainty about this potential
interaction is very large. Caused by inclusion and exclu-
sion criteria of the individual studies, estimates in the
outside range have the ﬂavour of an extrapolation into
regions where real data are missing.
Comparison to the original analysis
The primary analysis of this study was based on an
imputed data set including 2299 patients. In the original
analysis, we considered the complete case data set for the
primary analysis (N=1814 at lowest) and conducted one
sensitivity analysis based on an imputed data set
(n=2299), which did not change the conclusion of the
primary analysis. Also, in the original analysis, higher
PEEP ventilation strategies improved outcome in patients
with moderate and severe ARDS at baseline as deﬁned by
a PaO2/FiO2 ratio <200 mm Hg (p value for interaction
0.02).6 However, when we assessed the interaction using
Table 2 p Values for each interaction between the
continuous baseline predictor and PEEP intervention for
each outcome in the three included trials
Trial/predictor
60 days
mortality
Time to
death
Time to
unassisted
breathing
LOVS
BMI 0.7331 0.3537 0.7507
Estimated RC 0.1078 0.0957 0.3264
PaO2/FiO2 0.1247 0.0296 0.0325
Oxygenation
index
0.4337 0.1259 0.2594
EXPRESS
BMI 0.6989 0.7091 0.7294
Estimated RC 0.6922 0.7053 0.4629
PaO2/FiO2 0.5511 0.6095 0.7587
Oxygenation
index
0.3287 0.3041 0.9492
ALVEOLI
BMI 0.1844 0.0894 0.8589
Estimated RC 0.5438 0.7938 0.1192
PaO2/FiO2 0.9785 0.7647 0.2002
Oxygenation
index
0.7908 0.8835 0.8046
BMI, body mass index; FiO2, fraction of inspired oxygen; PaO2,
arterial partial oxygen pressure (mm Hg); PEEP, positive
end-expiratory pressure; RC, respiratory compliance (tidal volume
in mL/inspiratory plateau pressure−PEEP in mm Hg).
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the continuous variable assuming linearity, no signiﬁcant
interaction was observed. Of note, we did not investigate
the possible interaction graphically as we did using TEF
plots in the analysis reported herein. Therefore, we previ-
ously reasoned about a possible threshold effect rather
than a continuous interaction.6
At the time of our previous analysis,6 the new ARDS
categorisation (mild 200–300 mm Hg PaO2/FiO2, mod-
erate 100–200 mm Hg PaO2/FiO2 and severe
<100 mm Hg PaO2/FiO2) was not deﬁned.
3 Considering
these proposed cut-points, the qualitative assessment of
the TEF for PaO2/FiO2 from our MFPI analysis suggests
that some patients with moderate and severe ARDS may
beneﬁt from higher PEEP ventilation strategies. The
results from our MFPI analysis do not contradict the sub-
group effect initially identiﬁed in the previous analysis,6
but they provide further information and allow for a
more comprehensive assessment of the interaction using
the resulting plot of the TEF adjusted for potential con-
founders. This is a critical issue, because relying on
statistical signiﬁcance without any qualitative investiga-
tion of the interaction may discard important informa-
tion that could be useful in clinical decision-making and
management, and to generate new hypotheses that
could be speciﬁcally tested in future trials. In this case,
the advisability of using a high PEEP strategy is most
compelling for patients with PaO2/FiO2 ratios of ∼100–
150, with values outside of this range being less compel-
ling, and with no suggestion of beneﬁt with higher
PEEP in values above 200.
The averaged TEF of BMI suggested that patients with
a BMI≥35 kg/m2 may beneﬁt more from higher PEEP
ventilation strategies compared to patients with lower
BMI, but CIs still include harm with higher PEEP in
these patients. In the previous analysis,6 we hypothesised
that in patients with high BMI, increased PEEP would
not improve outcome, because of fewer recruitable lung
units.6 Thus, the apparent interaction is opposite to the
direction proposed on the basis of physiological ration-
ale, further reducing the strength of inference.
Figure 3 Weights for the averaged TEFs in figure 2. Fixed-effects weights were derived from the reciprocal of the variances.
The shape of these curves is a result of the distribution of events and therefore also of the patient population by the respective
modifier. BMI, body mass index; OI, oxygenation index; PaO2/FiO2. PaO2/FiO2 ratio; RC, respiratory compliance; TEF, treatment
effect function.
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Strengths and limitations
An MFPI analysis uses all available information from a
continuous variable without linearity assumption and
the result does not depend on any cut-point for an inter-
action analysis. A large simulation study showed that the
MFPI approach adheres to the chosen signiﬁcance level
and that the power to identify an interaction is much
greater than the power of the popular approach based
on one cut-point.31 32 For this meta-analysis, all trials
provided individual patient data, and therefore we could
use all available information from the included trials to
compare the two PEEP strategies and to investigate
whether any of the four continuous variables modiﬁed
the treatment effect. Strengths of this analysis include an
explicit study protocol and analysis plan in which we
comprehensively described the clinical variables to be
investigated for interaction with the assigned interven-
tion. The study protocol was registered online and is
freely accessible.19 There is one additional eligible ARDS
trial, which has recently completed recruitment of 224
patients (NCT00431158). Since the sample size is small,
it is unlikely that it would inﬂuence results.
Although the overall sample size (2299 patients) is
large for the focus of many clinical trials in the intensive
care setting, our MFPI analysis remains underpowered.
From single trials, investigation of interactions requires
much larger sample sizes than investigations of main
effects. The three trials considered here were powered
to detect a main effect. Summarising results from three
trials increased statistical power of conducted subgroup
analyses, but the relatively large CIs of the TEFs, espe-
cially at both extreme ends of the continuous predictors,
indicate that still more patients and events would
strengthen the inferences of these analyses.
For the averaged TEFs, some researchers and clini-
cians may like to see a p value. There are various
methods to combine p values from several trials. We
could have provided a p value but it would have
depended on the speciﬁc method chosen. More meth-
odological research is required before we feel conﬁdent
to provide a p value. More important, we believe that
TEFs provide a much better way to investigate whether a
continuous variable has an inﬂuence on the comparison
of two treatments. In the TEF approach, observers can
infer statistical signiﬁcance from the positions of the
95% CIs. It is well known that CIs from models derived
in a data-dependent way are too small. Obviously, that is
also a critical issue of our pointwise CIs, speciﬁcally at
the outer range of the covariate distribution. For more
information, we refer interested readers to a dedicated
website.27
Authors have proposed credibility criteria to judge
whether observed interactions in clinical trials are likely
or unlikely to represent true effects. These criteria
include prespeciﬁcation, consistency across closely
related outcomes and the independence of the inter-
action from other prognostic factors.33 All of our inter-
action analyses were adjusted for recognised and
important factors, but only the MFPI analysis of PaO2/
FiO2 revealed consistent ﬁndings across all three prespe-
ciﬁed outcomes; the consistency strengthens the conclu-
sion that patients with moderately severe ARDS may
beneﬁt from higher PEEP ventilation.
Our results suggest that patients with a higher respira-
tory system compliance around 40 (tidal volume in mL/
(inspiratory plateau pressure−PEEP)) and above
(usually seen with milder ARDS) are more likely to
beneﬁt from higher PEEP. This appears counterintuitive
when viewed together with the results on PaO2/FiO2 or
oxygenation index, which suggested a beneﬁt for
patients with more severe ARDS. On the one hand, this
may support our hypothesis that most recruitable lung
units are found in patients with more severe ARDS
whose lungs are not severely non-compliant. On the
other hand, there were missing values for respiratory
system compliance in over 20% of patients (500/2299
patients) that we imputed for the present analysis; this
adds to the uncertainty about the effect estimates of the
analyses with respect to respiratory system compliance.
Practical experiences with MFPI analyses are limited;
however, some examples have illustrated its useful-
ness,13 34 and computer simulations have generated
compelling evidence.31 32 Recently, Bratton et al35
reported on a meta-analysis using the MFPI approach to
investigate whether continuous positive airway pressure
treatment has an impact on lowering blood pressure in
patients with obstructive sleep apnoea syndrome. In con-
trast to our study, the outcome of interest was continu-
ous (blood pressure); however, the applied method of
ﬁtting and averaging the functions over different trials
followed the general idea of our approach and the same
programmes were used. More practical experience and
methodological research is needed to combine MFPI
and the approach for a meta-analysis of functions.
Finally, a recent mediation analysis of 3562 patients with
ARDS enrolled in 9 RCTs suggested that the main medi-
ator of survival beneﬁts from lung-protective ventilation
is a minimised driving pressure (ΔP=tidal volumes/
respiratory system compliance).36 Higher PEEP together
with lower end-inspiratory (plateau) airway pressures
and lower tidal volumes may constitute important com-
ponents of lung-protective ventilation but ‘PEEP incre-
ments might be protective only when the increased
PEEP values result in a change in lung mechanics so
that the same tidal volumes can be delivered with a
lower ΔP’.36 The driving pressure can be easily calcu-
lated for patients who are not making inspiratory efforts
as the plateau pressure minus PEEP. However, before
this concept is implemented in critical care practice,
clinical trials are needed to test ventilator changes
(including PEEP) that lead to changes in ΔP.
Conclusions
If individual patient data are available, the MFPI
approach is a suitable method to investigate interactions
between continuous predictors and outcomes in a
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meta-analysis, avoiding arbitrary cut-points and linearity
assumptions. The results of this study do not allow for
deﬁnite conclusions regarding clinical practice due to
limited statistical power; however, we found evidence
that higher PEEP ventilation is beneﬁcial in some
patients with moderate ARDS. Furthermore, in view of
the increasing prevalence of obesity,37 the potential
interaction between BMI≥35 kg/m2 and higher PEEP
levels should be addressed in future trials to optimise
ventilation strategies in this growing patient population.
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